|
How the cluster effect - and cross fertilization - can nurture Arizona's Bioscience future
"Biotech is the future," according to Bruce Wright, associate vice president for economic development for the University of Arizona. And to make that future possible, a 65-acre Bioscience Park is being planned for Tucson.
According to Wright, "We are very strong in the life sciences, medicine, and biosciences, but our ability to successfully compete nationally and internationally for these firms depends on our ability to have adequate and available space for them to come to Tucson."
While the first phase would encompass 660,000 square feet of space, it could ultimately encompass a massive three million square feet of business space.
If Arizona's experience mirrors that of Europe, the industry will be given a huge boost - simply because of the cluster effect achieved in creating a centre of excellence. While the US remains the world's top location for life sciences clusters, Europe also has powerful Life Science players.
In fact, UK companies account for 40% of biotech products in the pipeline by European public companies, and a massive 45% of new biotech drugs in late-stage clinical trials in Europe.
The UK has developed a hugely successful development policy of creating bioscience parks close to major universities - such as Cambridge and Oxford. Being close to a number of smaller Universities in less prestigious locations also enables companies to recruit quality staff and set up collaborative research programs. The Thames Gateway's Kent Science Park is a scientific cluster that rivals some of the best in Europe. Home to 80 companies including Pfizer, Harada, and MDS Pharma, it taps into the best strengths of 11 local Universities.
Further West, the Thames Valley is home to companies including Bayer, Wyeth, and Celltech, making it home to one of the country's largest life science clusters. It draws on research- intensive universities that include the University of Reading.
Click here for more on this story
Other news
|